medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 2

<< Back

Ann Hepatol 2013; 12 (2)

Cirrhosis is less cirrhosis without virus C

Llorca R, Funuyet J, Romero-Gómez M

Language: English
References: 13
Page: 341-342
PDF size: 61.53 Kb.


Text Extraction

Article commented

Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, et al. Association between sustained virological response and all-cause mortality among patient with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.

COMMENTS
In the current commented article, van der Meer, et al. demonstrated that sustained virological response in patients with advanced fibrosis was associated with lower overall mortality, lower liver-related mortality including liver failure and liver cancer. No patient achieving sustained virological response required liver transplantation and liver-related mortality was more than 15 times lower (30 vs. 2%). Hepatocellular carcinoma rate was also reduced in comparison with non-responders but a significant risk remained. Cumulative HCC occurrence was 5.1% at 10 years vs. 21.8% in non-SVR. Genotype 3a, type 2 diabetes mellitus, older age, male gender, heavy alcohol consumption and histological cirrhosis were associated with increased risk of liver cancer.


REFERENCES

  1. Van der Meer AJ, Veldt BJ, Feld JJ, Wedemaeier H, Dufour JF, Lammert F, Duarte-Rojo A, et al. Association between sustained virological response and all-cause mortality among patient with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.

  2. Pol S, Carnot F, Nalpas B, Lagneau JL, Fontaine H, Serpaggi J, Serfaty L, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004; 35: 107-12.

  3. Hernandez R. A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. World J Gastroenterol 2012; 18: 4145-9.

  4. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-80.

  5. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne-Carrie N, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011; 96: 2601-8.

  6. Qin L, Wang Y, Tao L, Wang Z. AKT down-regulates insulinlike growth factor-1 receptor as a negative feedback. J Biochem 2011; 150: 151-6.

  7. Siddique A, Kowdley KV. Insulin Resistance and Other Metabolic Risk Factors in the Pathogenesis of Hepatocellular Carcinoma. Clin Liver Dis 2011; 15: 281-96.

  8. Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 2012; 24: 981-90.

  9. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010; 30: 750-8.

  10. Lisa B, Wagner V, Rinella M. The role of insulin-sensitizing agents in the treatment of non alcoholic steatohepatitis. Ther Adv Gastroenterol 2011; 4: 249-63.

  11. Guo L, Xie B, Mao Z. Autophagy in Premature Senescent Cells Is Activated via AMPK Pathway. Int J Mol Sci 2012; 13: 3563-82.

  12. Zajkowicz A, Rusin M. The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases. Mech Ageing Dev 2011; 132: 543-51.

  13. Razavi H. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013 [In press].




2020     |     www.medigraphic.com